Cipla Ltd.

Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (USFDA).

The company’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is APrated generic version of Shire’s Firazyr. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. According to IQVIA (IMS Health), Firazyr and its generic equivalents had US sales of approximately $270 million for the 12month period ending May 2020.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.